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Aims Lectin-like oxLDL receptor-1 (LOX-1) mediates the uptake of oxidized low-density lipoprotein (oxLDL) in endothelial
cells and macrophages. However, the different atherogenic potential of LOX-1-mediated endothelial and macrophage
oxLDL uptake remains unclear. The present study was designed to investigate the in vivo role of endothelial LOX-1 in
atherogenesis.
Methods
and results
Endothelial-specific LOX-1 transgenic mice were generated using the Tie2 promoter (LOX-1TG). Oxidized low-density
lipoprotein uptake was enhanced in cultured endothelial cells, but not in macrophages of LOX-1TG mice. Six-week-old
male LOX-1TG and wild-type (WT) mice were fed a high-cholesterol diet (HCD) for 30 weeks. Increased reactive
oxygen speciesproduction, impairedendothelial nitric oxide synthase activity and endothelial dysfunctionwere observed
in LOX-1TG mice as compared with WT littermates. LOX-1 overexpression led to p38 phosphorylation, increased
nuclear factor kB activity and subsequent up-regulation of vascular cell adhesion molecule-1, thereby favouring macro-
phage accumulation and aortic fatty streaks. Consistently, HCD-fed double-mutant LOX-1TG/ApoE2/2 displayed oxida-
tive stress and vascular inflammation with higher aortic plaques than ApoE2/2 controls. Finally, bone marrow
transplantation experiments showed that endothelial LOX-1 was sufficient for atherosclerosis development in vivo.
Conclusions Endothelial-specific LOX-1 overexpression enhanced aortic oxLDL levels, thereby favouring endothelial dysfunction,
vascular inflammation and plaque formation. Thus, LOX-1 may serve as a novel therapeutic target for atherosclerosis.
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Introduction
Oxidized low-density lipoprotein (oxLDL) is internalized by en-
dothelial cells and macrophages and its accumulation in the subendo-
thelial space is a key event preceding plaque formation. 1,2 Plasma
levels of oxLDL are increased in both experimental and human
atherosclerosis. While in macrophages, oxLDL is internalized by
several receptors such as scavenger receptor A (SR-A), CD36, and
CD68,3 in endothelial cells, its uptake depends solely on LOX-1.4
LOX-1 is a type II membrane glycoprotein that has a C-terminal
extracellular C-type lectin-like domain, which is essential for binding
to oxLDL.5
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Endothelial dysfunction induced by oxLDL has been implicated in
atherogenesis.6 Moreover, LOX-1 expression is increased in athero-
sclerotic plaques and its genetic deletion is associated with reduced
plaque formation in hypercholesterolemic mice.7 –9 In endothelial
cells, oxLDL-induced activation of LOX-1 triggers the expression
of inflammatory genes involved in endothelial dysfunction and
atherogenesis such as monocyte chemotactic protein-1 (MCP-1),
intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhe-
sion molecule-1 (VCAM-1).10,11 Moreover, LOX-1 activation in
vitro reduces nitric oxide (NO) availability via increased reactive
oxygen species (ROS) generation.12 Although these studies provided
interesting insights on the putative role of LOX-1 in atherogenesis,
the in vivo effects of endothelial LOX-1 activation remain to be
elucidated.
To specifically explore the role of LOX-1 in the vascular endothe-
lium, endothelial-specific LOX-1 transgenic mice were generated
using the Tie2 promoter (LOX-1TG). We found that endothelial-
specific overexpression of LOX-1 is associated with atherosclerotic
features resulting from increased oxidative stress and NFkB-driven
inflammation. Our results highlight opportunities for selective inhib-
ition of LOX-1 in conditions of hypercholesterolemia.
Methods
Generation of LOX-1 transgenic mice
To obtain mice overexpressing LOX-1 in endothelial cells, a murine tyro-
sine kinase receptor Tie2 promoter was used (Figure 1A). Targeted LOX-1
gene expression in endothelial cells was achieved using the coding se-
quence for the murine LOX-1 gene inserted into the expression vector
pSP14/15, which contains the murine 2 kb Tie2 promoter together
with 10 kb Tie2 enhancer originated from intron 1 of the endogenous
murine Tie2 gene (the pSP14/15 vector was a kind gift of Thomas
N. Sato, MD, PhD, University of Texas, TX, USA) (see Supplementary
material online, Methods).
To obtain LOX-1/ApoE2/2 double-mutant mice, hemizygous LOX-1
transgenic mice from the line, carrying maximal number of copies of
the transgene, were cross-bred with homozygous ApoE knockout
mice on a C57BL/6 background. Offsprings carrying the LOX-1 transgene
and being heterozygous for the ApoE locus were used to generate
LOX-1TG/ApoE2/2 mice (see Supplementary material online, Methods).
All animal experiments were performed on male mice. All procedures
were in accordance with institutional guidelines and approved by the
local animal committee.
Bone marrow transplantation
Bone marrow transplantation experiments were performed as
described13 (for details, see Supplementary material online, Methods).
Diet, tissue harvesting and processing
See Supplementary material online, Methods.
Plaque quantifications
Serial cross sections of the aortic root (8 mm thickness) from LOX-1TG
and corresponding C57BL/6 wild-type (WT) mice were cut and thaw-
mounted on glass slides for oil red O staining. For quantification of ath-
eroscleroticplaques in LOX-1TG/ApoE2/2 andApoE2/2mice,en faceana-
lysis of thoraco-abdominal aortas was performed as described.14 Plaque
area was visualized by fat staining (oil red O), photographed with a digital
camera (Olympus DP70, 12.5 megapixels) that was mounted on
binocular microscope (Olympus Schweiz AG), and quantified (Analysis
5; SoftImaging System).
Plasma lipids
Plasma cholesterol and triglycerides levels were determined using
InfinityTM Cholesterol, InfinityTM Triglycerides (Thermo Electron Cor-
poration Standard) and MC Cal (Abbott) (see Supplementary material
online, Methods).
Oxidized low-density lipoprotein
measurements
To determine mouse oxLDL concentrations in mouse serum and aorta
homogenates isolated from 12- to 14-week-old LOX-1TG and corre-
sponding WT male mice, commercially available Mouse Oxidized Low
Density Lipoprotein ELISA Kit (Cusabio Biotech, Wuhan, PR China)
was used according to the manufacturer’s instructions.
Endothelium-dependent relaxation of
intact aorta
The thoracic aortas of ApoE2/2 and LOX-1TG/ApoE2/2 mice were iso-
lated after 20 weeks of HCD. Aortas were dissected, excised and
placed into cold modified Krebs–Ringer solution of the following com-
position (mM): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, NaHCO3
25.0, KH2PO4 1.18 and calcium disodium EDTA 0.026, glucose 11.1
(control solution). The aortic rings (2 mm in length) were suspended in
organ chambers containing control solution (378C) aerated with 95%
O2 and 5% of CO2. They were connected to a force transductor (Power-
lab Model ML785 and ML119). Changes in isometric tension were
recorded. The rings were stretched progressively to their optimal
resting tension (0.75 g) and were allowed to equilibrate for 90 min. Con-
centration–responsecurves wereobtained in acumulativeway.Tostudy
endothelium-dependent relaxations to acetylcholine, the preparations
were exposed to U 46619 [in order to obtain 50–70% of response to
KCl (60 mM)]. Sodium nitroprusside (SNP) was applied to study
endothelium-independent relaxation.
Measurement of total reactive oxygen species
production by electron spin resonance
spectroscopy
Total levels of ROS were determined in murine descending aorta sec-
tions by electron spin resonance (ESR) spectroscopy using the spin
probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine
and an e-scan ESR spectrometer (Bruker). The intensity of ESR spectra
was quantified after calibration of ESR signals with the free radical
3-carboxy-2,2,5,5-tetramethyl-1-pyrrolidinyloxy. The intensity values
were divided by the dry weight of aorta sections.
Isolation of murine endothelial cells
Murine aortic endothelial cells were isolated as described15 (for details,
see Supplementary material online, Methods).
Lipid uptake
Endothelial cells or macrophages were stimulated with 10 mg/mL
Dil-oxLDL (Intracel).16,17 After 6 h cells were harvested and stained
with anti-mouse CD105 antibody (Pharmingen), followed by incubation
with FITC-labelled anti-rat secondary antibody (Molecular Probes).
Mean fluorescence was monitored with FACS (BD, Canto II) and analysis
of the data was performed using FlowJo software.
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Figure 1 Generation and characterization of endothelial-specific LOX-1TG mice. (A) Scheme of endothelial-specific LOX-1 transgenic construct.
(B) Southern blot analysis of F1 generation. Genomic DNA isolated from tail biopsies was digested with BamHI, and hybridized with LOX-1-specific
radioactively labelled probe. The presence of additional BamHI restriction site located within LOX-1 cDNA introduced into murine genome upon
integration of the transgenic construct allowed to detect the corresponding band in transgenic lanes with the specific probe used. This band is absent
in wild-type lanes. (C) real-time polymerase chain reaction analysis. Total RNA isolated from either aorta (A) or kidney (K) of three different trans-
genic lines 5048.54, 5048.24, and 5048.1 are transformed into cDNA and amplified with LOX-1-specific primers. As a loading control, murine
S12-specific primers are used. Real-time-negative control without reverse transcriptase; M, 100 bp DNA molecular weight marker. (D) Western
blot of aortic lysates using anti-murine LOX-1 antibody. Anti-murine a-tubulin antibody is used as a loading control. Transgenic line 5048.1 (red
rectangle) is used for all subsequent experiments. (E) Aortic cross sections from C57BL/6 wild type (left) and LOX-1TG (right) are stained with anti-
murine LOX-1 antibody. Bar ¼ 100 mm. (F) Murine endothelial cells isolated from LOX-1TGmice and stimulated with DiI-oxidized low-density lipo-
protein for 6 h, reveal increased oxidized low-density lipoprotein uptake compared with endothelial cells from wild-type mice as shown by oil red O
staining and monitored by FACS with an anti-mouse CD105 antibody. Quantification of FACS measurements is given as mean fluorescence of the
CD105-positive cells; n ¼ 4 for each group, **P, 0.01.
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RT–PCR analysis, immunohistochemistry
and western blotting
See Supplementary material online, Methods.
Statistical analysis
Data are presentedas mean+ SEM. Statistical significancewascalculated
using either ANOVA with post hoc Tukey’s test or Student’s unpaired
t-test. Significance at the level of two-tailed P, 0.05 was accepted for
the corresponding statistical analysis.
Results
Generation and molecular
characterization of LOX-1 transgenic mice
To obtain mice overexpressing LOX-1 in endothelial cells, a murine
tyrosine kinase receptor Tie2 promoter was used (Figure 1A). Mice
overexpressing LOX-1 in endothelial cells carried a different copy
number of LOX-1 transgene (Figure 1B). The line 5048.1, which
showed the highest transgene expression, was selected for further
experiments (Figure 1B through D). LOX-1 expression was the
highest in the aorta, while lower expression levels were observed
in the kidney (Figure 1C). Increased aortic expression of LOX-1 in
transgenic mice was confirmed by Western blot (Figure 1D). In con-
trast, LOX-1wasnot detectable in WTlittermates (Figure1D). Immu-
nohistochemistry confirmed that overexpression of LOX-1 was
confined to the vascular endothelium (Figure 1E). Moreover,
oxLDL uptake was increased only in endothelial cells isolated from
LOX-1TG but not WT mice (Figure 1F). Importantly, in cultured
macrophages oxLDL uptake did not differ between LOX-1TG and
WT mice (Supplementary material online, Figure S1). Plasma lipopro-
tein levels remained unchanged in transgenic mice compared with
their WT littermates (Table 1). In contrast, vascular oxLDL levels
were increased in LOX-1TGmice as compared with WT (Supplemen-
tary material online, Table S1) suggesting a key role of endothelial
LOX-1 for oxLDL uptake in vivo.
Endothelial LOX-1 overexpression
promotes fatty streak formation
To examine the effects of endothelial LOX-1 overexpression on the
initial stages of atherogenesis, we fed LOX-1TG and WT mice a high-
cholesterol diet (HCD) for 30 weeks (Figure 2A). In LOX-1TG mice,
aortic fatty streak formation was significantly increased (Figure 2B).
Upon initiation of plaque formation, oxLDL activates inflam-
matory pathways in vascular cells. In line with this concept,
immunohistochemical stainingsof aortas showed increasedendothe-
lial expression of VCAM-1 in LOX-1TG mice compared with WT
(Figure 2C). Adhesion molecules are important for recruiting inflam-
matory cells to the activated endothelium. Indeed, the number of
activated macrophages, as assessed by the number of CD68-positive
cells, was increased in aortas of LOX-1TG mice (Figure 2D).
Endothelial LOX-1 overexpression on
ApoE background increases
atherosclerosis
To investigate whether LOX-1 overexpression plays a role in plaque
formation, LOX-1TG mice were crossed with apolipoprotein E knock-
out (ApoE2/2, C57BL/6 background) mice, a widely used mouse
model for studying atherosclerosis.18 The resulting LOX-1TG/
ApoE2/2 and ApoE2/2 male littermates were fed a HCD for
20 weeks (Figure 3A). Interestingly, en face plaque area was almost
two-fold increased in LOX-1TG/ApoE2/2 as compared with ApoE2/2
littermates (Figure 3B). To determine the effects of endothelial-specific
LOX-1 overexpression on vascular inflammation, immunohistochem-
ical staining for VCAM-1 and P-selectin was performed on cross sec-
tions of aortic roots. Morphometric analyses revealed increased
expression levels of VCAM-1 and P-selectin in LOX-1TG/ApoE2/2
(Figure 3C and Supplementary material online, Figure S2). mRNA ana-
lysis for VCAM-1 confirmed these results (data not shown). In addition,
thenumberofplaquemacrophages (CD68-positive area; Figure3D) and
T-cells (CD3-positive area; Figure 3E) was increased in LOX-1-1TG/
ApoE2/2 mice.
To understand whether endothelial LOX-1 is required for
atherosclerosis development in vivo, bone marrow transplantation
experiments were performed. Bone marrow cells isolated from
ApoE2/2 or LOX-1-1TG/ApoE2/2 donor mice were transplanted
into irradiated 5-week-old recipient ApoE2/2 and LOX-1-1TG/
ApoE2/2mice (Supplementary material online, Figure S3A). Chimeric
LOX-1-1TG/ApoE2/2 recipient mice receiving either ApoE2/2 or
LOX-1-1TG/ApoE2/2 bonemarrowcells still showedmoreatheroscler-
oticplaques than those recipientApoE2/2mice receiving either bone
marrow (Supplementary material online, Figure S3B). In addition,
immunostaining of aortic cross section from ApoE2/2 and
LOX-1-1TG/ApoE2/2 mice kept 20 weeks on HCD with LOX-1 and
CD68 showed no LOX-1 expression in activated macrophages
(Supplementary material online, Figure S3C). Finally, FACS analysis
of blood and spleen samples from transplanted mice revealed no dif-
ference in frequencies of monocytes, T-cell subtypes or macro-
phages (Supplementary material online, Figure S4).
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Table 1 Plasma lipid profiles in wild-type, LOX-1TG, ApoE2/2, and LOX-1TG/ApoE2/2 mice
WT (n5 5) LOX-1TG (n5 6) ApoE2/2 (n 5 8) LOX-1TG/ApoE2/2 (n5 10)
Total cholesterol (mmol/L) 5.64+1.20 6.27+0.94 19.97+2.98** 16.98+2.83**
Triglycerides (mmol/L) 0.77+0.07 0.75+0.03 0.84+0.18 1.13+0.28
Free fatty acids (mmol/L) 0.30+0.06 0.28+0.08 0.36+0.06 0.44+0.07
Statistical significance was calculated using analysis of variance. **P, 0.005 compared with wild-type and LOX-1TG, mean+ SEM.
A. Akhmedov et al.2842
LOX-1 overexpression increases reactive
oxygen species production and
inflammation
As endothelial dysfunction precedes plaque formation, we assessed
endothelium-dependent vasorelaxation to acetylcholine in isolated
aortic rings obtained from WT, LOX-1TG, ApoE2/2 and LOX-1TG/
ApoE2/2 mice. Whereas no difference was seen in endothelium-
dependent vasorelaxation to acetylcholine between LOX-1TG and
WT mice, in LOX-1TG/ApoE2/2 mice, acetylcholine-induced en-
dothelium-dependent vasorelaxation was impaired (pEC50 (2log
M): 6.34+0.12); Emax (% of contraction) 6.52+ 3.05% compared
with that of ApoE2/2 mice (6.67+0.40, P, 0.05; Emax (% of con-
traction) 22.18+6.68%, P, 0.05) (Figures 4A and 5A, respectively).
In contrast, endothelium-independent relaxation to SNP was similar
(data not shown). Next, we tested whether impaired endothelial
function would have any impact on endothelial nitric oxide synthase
(eNOS) activity. Indeed, eNOS activation through phosphorylation
was markedly reduced in both LOX-1TG and LOX-1TG/ApoE2/2
mice (Figures 4B and 5B, respectively; Supplementary material
online, Figure S5A). Since eNOS is known to be redox sensitive and
thus can be regulated by ROS, we measured ROS in aortas isolated
from LOX-1TG and LOX-1TG/ApoE2/2. Aortic levels of ROS in both
transgenic groups were markedly increased compared with corre-
sponding littermate controls, but they decreased when aortas from
both LOX-1TG and LOX-1TG/ApoE2/2 were pre-incubated with super-
oxide dismutase, a known scavenger of superoxide (Figures 4C and 5C,
respectively).
LOX-1 receptor activation leads to accumulation of ROS and in
turn activates a cascade of redox-sensitive events including MAPK
Figure2 Increased aortic fatty streak formation, expression of VCAM-1, and CD68 in LOX-1TGmice. (A) Scheme of the diet set up. Six-week-old
male LOX-1TG and wild-type control mice kept on normal chow diet were then fed a high-cholesterol diet for additional 30 weeks. (B) Immunostain-
ing of aortic roots from LOX-1TGmice 30 weeks after high-cholesterol diet showed increased lipid accumulation as assessed byoil red O stainingwith
corresponding quantification. Immunohistochemistry of aortic roots from LOX-1TG mice for (C) VCAM-1 and (D) CD68 showed increased inflam-
mation compared with wild-type mice; n ¼ 10 for wild-type and n ¼ 8 for LOX-1TG, *P, 0.05. Values are expressed as mean+ SEM.
Bar ¼ 100 mm.
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pathways.12,19– 22 To test this in our setting, both protein expression
and phosphorylation of p38 MAPK were assessed in LOX-1TG aortic
lysates and were both increased compared with non-transgenic
controls (Figure 4D and Supplementary material online, Figure S5B).
Further, activation of the redox-sensitive transcription factor
nuclear factor kB (NFkB) was increased in LOX-1TG mice due to
increased binding of the p65 subunit of NFkB to DNA (Figure 4E).
Finally, we assessed the expression of VCAM-1 and E-selectin, both
known to be regulated by ROS through NFkB.23 Indeed, mRNA
expression of VCAM-1 and E-selectin was higher in aortic lysates
obtained from transgenic mice (Figure 4F and Supplementary material
online, Figure S5C).
Figure 3 Increased aortic plaque formation and inflammation in LOX-1TG/ApoE2/2 mice. (A) Twenty-six-week-old mice were sacrificed for tissue
isolation. Six-week-old male LOX-1TG/ApoE2/2 and ApoE2/2 mice kept on normal chow diet were fed a high-cholesterol diet for 20 weeks (lower
panel). Twenty-six-week-old mice were euthanized for tissue harvesting. (B) En face plaque staining with corresponding quantification of
thoraco-abdominal aortas from LOX-1TG/ApoE2/2 mice after 20 weeks of high-cholesterol diet showed increased lipid accumulation; n¼ 12 for
ApoE2/2 and n¼ 9 for LOX-1TG/ApoE2/2, *P, 0.05. (C) Immunostaining of aortic roots from LOX-1TG/ApoE2/2 and ApoE2/2 mice with
VCAM-1 antibody with corresponding quantification; n ¼ 7; *P, 0.05. (D, E) Cross sections of aortic roots from LOX-1TG/ApoE2/2 mice
stained with (D) antibody against CD68, or (E) antibody against CD3 (arrows indicate positive staining) showed increased macrophage and
T cell accumulation compared with ApoE2/2 mice; n ¼ 7 for each group, *P, 0.05. Bar ¼ 500 mm (C, D) and 100 mm (E). Values are expressed
as mean+ SEM. Statistical significance was calculated using unpaired Student’s t-test.
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Discussion
In the present study, we sought to elucidate whether and through
which mechanisms endothelial LOX-1 accelerates fatty streak
formation and atherosclerosis development. To this end, we gener-
ated Tie2-LOX-1TG mice with endothelium-targeted LOX-1 overex-
pression and compared the development of atherosclerosis in these
mice and their WT littermates. Our results suggest that endo-
thelial LOX-1 is critically involved in the development of endothelial
dysfunction, vascular inflammation and atherosclerotic lesions.
Several linesofevidencesupportourconclusions: (i) endothelial-specific
LOX-1overexpressionaccelerates fatty streak formation, inducesadhe-
sion molecule expression, and increases macrophage recruitment;
(ii) LOX-1 overexpression in ApoE2/2 mice causes endothelial
Figure4 Increased fatty streaks are associated with decreased endothelial nitric oxide synthase phosphorylation, increased ROS levels, p38 phos-
phorylation and NFkB activation in LOX-1TGmice. (A) Relaxation to acetylcholine in aortic rings from WT (blue line) and LOX-1TG (black line). Values
were normalized to preconstruction with U46619 and shown as mean+ SEM. n ¼ 6 per genotype. (B) Western blot reveals decreased endothelial
nitric oxide synthase activation through phosphorylation of Ser1177 residue in aortic lysates from LOX-1TGmice. Quantification of protein expression
is given as ratio to total endothelial nitric oxide synthase expression levels; n ¼ 4 for each group, *P, 0.05. Statistical significance was calculated with
unpaired Student’s t-test. (C) Measurements of total ROS production by ESR spectroscopy in aortas show increased ROS levels in LOX-1TGmice com-
pared with WT controls. Pre-treatment of aortas from LOX-1TGmice with 150 U/mL superoxide dismutase (SOD) significantly reduces ROS accumu-
lation. Quantification is given as a percentage of average control value; n ¼ 6 for each group, *P, 0.05. (D) Western blot shows increased p38
phosphorylation in aortic lysates from LOX-1TG mice. Quantification of protein expression is given as ratio to total p38 expression levels; n ¼ 4 for
each group, *P, 0.05. (E) Increased p38 phosphorylation is further associated with increased nuclear translocation and binding capacity of NFkB as
shown by DNA-binding assay for RelA/p65 subunit of NFkB in aortic lysates. Quantification of binding activity is given as mean absorbance and normal-
ized to the average value of unstimulated LOX-1TGendothelial cells; n ¼ 6 foreach group, *P, 0.05. (F) Increased NFkB further activates expression of
inflammation molecule VCAM-1. The VCAM-1 mRNA was analysed by quantitative real time PCR. RNA was normalized to the internal control S12
(n ¼ 6 in each group). Data are shown as percentage of WT average. Values are expressed as the mean+ standard error of mean (SEM). *P, 0.05
vs. control wild-type (WT) mice.
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dysfunction and accelerates plaque formation; (iii) endothelium-
targeted LOX-1 overexpression increases aortic ROS production
and activates redox-sensitive pathways such as MAPK p38 and
NFkB, ensuing in endothelial inflammation.
Uptake of oxLDL by endothelial cells and macrophages is a key
event preceding plaque formation (i) and (ii). However, it is not clear
whetherendothelial LOX-1activation translates intoanatherolsclero-
tic phenotype in the vasculature. In the present study, we have demon-
strated that endothelial overexpression of LOX-1 accelerates
endothelial dysfunction in atherosclerosis-prone ApoE2/2 mice. This
finding is in line with the notion that LOX-1 antagonism improves
NO availability in the coronary circulation.24 Indeed, we have found
that in LOX-1TG mice LOX-1 overexpression induces oxidative
stress and reduces eNOSactivationwithout affectingendothelial func-
tion. In contrast, using LOX-TG1/ApoE2/2 mice, we have observed
impaired vasorelaxation to acetylcholine. We do speculate that in
LOX-1TGmice some compensatory mechanisms may still be operating
in the absence of a severe atherosclerotic phenotype. Another possi-
bility is that increased ROS production observed in LOX-1TGmice was
not sufficient to affect endothelium-dependent relaxation by such a
strong agonist as acetylcholine. Impaired vasorelaxation in LOX-1TG/
ApoE2/2mice were explained by reduced eNOS expression and acti-
vation as well as increased aortic ROS generation. Indeed,
eNOS-activating phosphorylation was blunted in LOX-1TG/ApoE2/2
mice, thus contributing to endothelial dysfunction observed in these
mice. Moreover, LOX-1-dependent oxidative stress led to phosphor-
ylation of MAPK p38 and subsequent activation of NFkB signalling.
These molecular events were associated with up-regulation of the in-
flammatory molecules VCAM-1, E- and P-selectin, favouring mono-
cytes recruitment. Moreover, phosphorylation of p38 is a key
initiator of the apoptotic process, thus precipitating vascular pathology
in vessels with LOX-1 activation.25,26 This first set of findings strongly
suggests that LOX-1overexpression in thevascularendothelium is key
event preceeding the atherogenic process. Indeed, LOX1-TG mice
without ApoE2/2 background already showed clear signs of vascular
inflammation together with an increased oxidative burden. The
strength of our work is the in vivo characterization of endothelial
LOX-1 in an unanticipated transgenic mouse model. The design of
this specific transgeneallowedustounderstand the relevanceofendo-
thelial LOX-1, regardlessof its role in macrophages.Notably, we could
show that selective activation of LOX-1 in the endothelium is sufficient
to induce early precursors of atherosclerotic disease such as
Figure5 Increased plaque formation is associated with endothelial dysfunction, decreased endothelial nitric oxide synthase phosphorylation and
increased ROS levels in LOX-1TG/ApoE2/2 mice. (A) Relaxation to increasing concentrations of acetylcholine in aortic rings from ApoE2/2 and
LOX-1TG/ApoE2/2 mice. Values were normalized to preconstruction with U46619 and shown as mean + SEM. ApoE2/2 (blue line), LOX-1TG/
ApoE2/2 (black line). n ¼ 8/genotype, *P, 0.05. (B) Western blot reveals decreased endothelial nitric oxide synthase activation throughphosphor-
ylation of Ser1177 residue in aortic lysates from LOX-1TG/ApoE2/2 mice. Quantification of protein expression is given as ratio to total endothelial
nitric oxide synthase expression levels; n ¼ 4 for each group, *P, 0.05. Statistical significance was calculated with unpaired Student’s t-test. (C)
Measurements of total reactive oxygen species production by electron spin resonance spectroscopy in aortas show increased reactive oxygen
species levels in LOX-1TG/ApoE2/2 mice compared with ApoE2/2 controls. Pre-treatment of aortas from LOX-1TG/ApoE2/2 mice with 150 U/
mL SOD significantly reduces reactive oxygen species accumulation. Quantification is given as a percentage of average control value; n ¼ 6 for
each group, *P, 0.05.
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endothelial dysfunction and NFkB-driven inflammation. Indeed,
macrophages did not show any up-regulation or functional activity of
LOX-1 in our genetic model, further strengthening the importance
of endothelial LOX-1 in atherogenesis. Although under certain condi-
tions the Tie2 promoter may also be active in macrophages,27,28 it
appears that other scavenger receptors play a more dominant role
for the oxLDL uptake in these cells. Indeed, our initial characterization
of the LOX-1TGmicerevealedhigh levelsofLOX-1transgenemRNAin
aortic endothelial cells, and lower levels in peritoneal macrophages.
However, functional assay of oxLDL uptake showed no difference
between transgenic and non-transgenic macrophages ruling out a con-
tribution of other scavenger receptors such as SR-A and SR-B under
ourexperimental conditions.Moreover, bonemarrowtransplantation
experiments together with immunostaining of atherosclerotic aortas
demonstrated that bone marrow-derived cells, in particular macro-
phages, do not account for the increase in atherosclerosis observed
in our LOX-1 transgenic mouse model. Thus, we were able to specif-
ically overexpress LOX-1 in the endothelium of mice in vivo and to
demonstrate distinct functional changes of endothelial cells, i.e. a
marked increase in oxLDL uptake as a crucial step in the atheroscler-
osis process.
Since plasma lipid levels were similar in LOX-1TG and WT mice, the
difference in fatty streak formation observed in transgenic mice must
be related to an increased activity of the LOX-1 receptor as demon-
strated in transgenic endothelial cells in culture. Indeed, aortic levels
of lipoproteins were augmented in LOX-1TG as compared with WT
littermates. Using a preproendothelin-1 promoter and a bovine
LOX-1 transgene, others found no phenotype of the transgene in
WT C57BL/6 mice, but an inflammatory intramyocardial vasculopa-
thy on the ApoE background.7 This discrepancy may be related to the
fact that the preproendothelin-1 promoter, unlike the Tie2promoter
used in our study, drives LOX-1 transgene expression predominantly
in microvessels rather than in conduit arteries that are prone to ath-
erosclerotic plaque formation. Furthermore, species differences
between bovine and murine LOX-1 gene may have contributed.
In summary, our data indicate that endothelial-specific overex-
pression of LOX-1 enhances lipid deposition and inflammation in
the aorta and leads to endothelial dysfunction and atherosclerotic
plaque formation. At the molecular level, LOX-1 activates p38-
NFkB pathway resulting in increased VCAM-1, E- and P-selectin tran-
scription, and vascular inflammation. As LOX-1 is also overexpressed
in human plaques, endothelial-specific inhibition of LOX-1 may
represent a new therapeutic target for the prevention and treatment
of atherosclerosis.
Study limitations
There are still some limitations applied for the present study which
need to be considered and addressed in the future. First of all, ex-
trapolation of data obtained in genetically modified mice to human
is always a difficult issue. Therefore, in order to support our conclu-
sion regarding clinical applications, further experiments on human
samples should be considered in the future. Second, the use of trans-
genic mice does not completely exclude the existence of alternative
LOX-1-dependent molecular pathways. Finally, smooth muscle cells
may also contribute to LOX-1-mediated atherogenesis, since the
basal expression of LOX-1 and the activity of Tie2 promoter have
been previously reported in these cells.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Pathological tricuspid regurgitation (TR) is more
often secondary due to annular dilatation and
increased tricuspid leaflet tethering. Although ring
annuloplasty is key to surgery for TR, surgical treat-
ment of TR in high-risk patients is associated with
increased mortality. Percutaneous single or dual
caval transcatheter heart valve-(THV)-prosthesis
implantation seems feasible, but not realizable in
many patients due to increased caval vein diameter.
In an 85-year-old woman with severe TR (Panels
A and B) associated with advanced right-heart
failure, ascites, and portal hypertension (Panel C)
at prohibitive risk for open-heart surgery (Euro-
SCORE 21.7), transesophageal echocardiography
(TEE) and multi-slice computed tomography
(MSCT) revealed inferior venacava (IVC) dilatation
(Panel D; 34× 43 mm).
To downsize the IVC to a mean diameter
,30 mm, surgicalbandingwasperformedvia right-
lateral mini-thoracotomy using a longitudinally-
opened goretex-prosthesis, which was ‘wrapped’
around the IVC below the diaphragm just after
the confluence of the hepatic veins, while a
30 mm Z-MED II valvuloplasty balloon was inflated
in that position. Thereafter, a balloon-expandable
stent (AndraStent-XXL, 35 mm, Andramed) was deployed within the banded IVC-segment, which was tightened with 5-0 Prolene-suture.
Finally, an Edwards-SAPIEN 29 mm was implanted into the stent (Panels E and F).
Although pacemaker leads in the superior vena cava (SVC) prohibited implantation of an upper caval valve, TR declined significantly
(Panels G–I), and general condition had significantly improved at discharge after 2 weeks (decreased ascites and peripheral oedema;
9 kg weight loss). TEE/MSCT showed trace-leakage with decrease of RV and RA volumes and hepatic vein diameters.
We conclude that in high-risk patients with severe TR and enlarged IVC, downsizing of IVC is feasible to enable THV implantation.
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